Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Mean Arterial Pressure
58%
Randomized Placebo-controlled Trial
55%
Cyclophosphamide
53%
Rituximab
53%
International Prognostic Index
53%
Doxorubicin
53%
Lymphoma Patients
53%
Prednisone
53%
Clinical Assessment
50%
Flumazenil
50%
Prognostic Model
50%
Oxygenation
50%
Benzodiazepine Receptor
50%
Initial Treatment
50%
Randomized Trial
50%
Immune Therapy
50%
Middle Cerebral Artery Velocity
50%
Cardiac Surgery
50%
Total Abdominal Hysterectomy
50%
Analgesic Effect
50%
Transversus Abdominis Plane Block
50%
PD-L2
50%
Reaction-based
50%
Appropriate Antibiotics
50%
Frontal Lobe
50%
Effector T Cells
50%
Multiplex PCR (mPCR)
50%
Intensive Care Unit
50%
Activated B Cells
50%
Seizure
50%
Acute Urinary Retention
50%
Randomized Controlled Trial
50%
Ultrasound Examination
50%
Fibrinogen Concentrate
50%
Procalcitonin
50%
Preemptive Treatment
50%
TRP Channels
50%
Melastatin
50%
Poor Survival
50%
Receptor Antagonist
50%
Postpartum Hemorrhage
50%
Cerebral Oxygenation
50%
Progression-free Survival
41%
Pain Score
37%
Ropivacaine
37%
Blood Transfusion
27%
Specific T Cells
26%
Postoperative Nausea
25%
LMO2
25%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Cyclophosphamide
53%
Rituximab
53%
Vincristine
53%
Prednisone
53%
Doxorubicin
53%
International Prognostic Index
53%
Fibrinogen Concentrate
50%
Focused Ion Beam
50%
Placebo
50%
Transient Receptor Potential Channel M4
50%
Mean Arterial Pressure
50%
Frontal Lobe
50%
Analgesic Activity
50%
Transient Receptor Potential Channel
50%
Urinary Retention
50%
Heart Surgery
50%
Clinical Assessment
50%
Multiplex Polymerase Chain Reaction
50%
Abdominal Hysterectomy
50%
B Cell
50%
Transversus Abdominis Plane Block
50%
Progression Free Survival
41%
Lung
40%
Morphine
37%
Ropivacaine
37%
Bladder
25%
Catheterization
25%
Coughing
25%
Heart Output
20%
